...Thanks. Good morning, everybody. It's a pleasure to be here. And so I see so many people in the room and welcome to those joining today online. So as you know, my name's Sarah Howell. I'm the CEO of Arecor Therapeutics. And we're here today to talk through our interim results for the six months ending June 30, 2024. So I'll draw your attention, as usual, to our customary legal notice. So I know, certainly, everybody in the room today knows the company pretty well now., but for anybody that's joining online that might be new to us today, I'll just give a really brief high-level view of the business. So it's our core very much focus on developing enhanced therapeutics that can transform quality of life and outcomes for patients. We do this by leveraging our innovative and proprietary formulation technology platform, Arestat, so we're developing novel formulations of existing therapies, SO existing medicines with improved properties. We have a very broad and diversified and the risk and portfolio...
